Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378117 | 1.00 | IRAK4 (0.37) | IRAK4LMNACTSD | |
| SCHEMBL9865626 | 0.91 | LMNA (0.39) | IRAK4LMNACTSD | |
| SCHEMBL5215585 | 0.91 | LMNA (0.39) | IRAK4LMNACTSD | |
| SCHEMBL4511068 | 0.90 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL4511069 | 0.90 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL5994524 | 0.84 | IRAK4 (0.42) | IRAK4CTSD | |
| SCHEMBL22354600 | 0.84 | IRAK4 (0.42) | IRAK4CTSD | |
| SCHEMBL14285588 | 0.75 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL5991543 | 0.75 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL4378121 | 0.75 | IRAK4 (0.35) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631355-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-1817033-B1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1722795-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-7326716-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1817033-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | Allergan, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7179820-B2 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2006058080-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-6977260-B2 | administering to an animal having ocular hypertension a piperidynly analog; a container adapted to dispense the ophthalmic solution in a metered form | ALLERGAN, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1585729-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004063158-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | PTGIR, PTGDR, PTGER1 | IRAK4 2972/4885LMNA 1622/4885CTSD 1728/4885 |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | SLC10A2, GUCY1B1, PTGER1 | IRAK4 830/4885LMNA 1832/4885CTSD 2049/4885 |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | PTGIR, PTGER1, PTGS1 | IRAK4 3561/4885LMNA 1654/4885CTSD 1901/4885 |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | C3AR1, C1R, HRH4 | IRAK4 1060/4885LMNA 1428/4885CTSD 160/4885 |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | PTGER1, PTGER2, PTGER4 | IRAK4 1196/4885LMNA 1940/4885CTSD 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.